ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Oct 4, 2017
Housing Market Very Strong But To “Face Two Contradicting Challenges”
Image Shown: The iShares US Home Construction ETF (ITB) has advanced ~ 24% year-to-date, according to data from YahooFinance. “Housing indicators may be leveling off,” per S&P Corelogic, and the threat of rising interest rates looms (as it has for years), but we like the fundamental strength that we’re seeing from the homebuilders of late, which has translated into strong equity performance.
Oct 3, 2017
Intel’s Stock Is Marching Ever Higher
Image Shown: Intel's shares have been catching a bid lately. Shares of newsletter portfolio idea Intel are cheap by our estimates, and the company sports a nice dividend yield to boot. Does it have further upside potential?
Sep 30, 2017
Will Texas Tea Hit $75 Per Barrel By Year’s End?
Image Shown: The performance of the VanEck Vectors Oil Refiners ETF (CRAK) since its launch in August 2015.We’ve witnessed our fair share of fits and starts from energy resource prices during the past few years, but could the global crude markets finally be rebalancing? Let’s talk about our thoughts on whether the outlook for energy resource pricing is improving in a sustainable way.
Sep 30, 2017
Amazon Casts a Large Shadow Over the Pharmacy Industry
Image Source:  Mike Mozart. It is our belief the food retailing industry is in the midst of widespread disruption with Amazon’s attempt to break into the supermarket game with its audacious purchase of Whole Foods. The Whole Foods acquisition is not likely to be an isolated one-off event; instead, it may be a harbinger of Amazon’s ambition to break into new markets, thus expanding its overall percentage of retail sales. We update our views on Amazon and how the company may eventually impact newsletter portfolio holding CVS Health.
Sep 29, 2017
Our Reports on Stocks in the For-Profit Education Industry
Image Source: GotCredit. Our reports on constituents in the For-Profit Education industry can be found in this article. Reports include ATGE, BPI, CECO, CPLA, EDU, LOPE, LRN, STRA, UTI.
Sep 25, 2017
Boeing, Visa Top Dow Performers Thus Far in 2017
Image Source: Ken Mist. Two of our favorite ideas have been leading the pack.
Sep 24, 2017
Dividend Increases/Decreases for the Week Ending September 22
Let's take a look at companies raising/lowering their dividends this week.
Sep 24, 2017
AT&T’s 5% Dividend Yield: Is It Sustainable?
Image Source: Mike Mozart. The question on everyone’s minds: Is AT&T’s dividend sustainable?
Sep 22, 2017
Microsoft’s Dividend Growth Doesn’t Disappoint
Image Source: Valuentum. Microsoft has been one of our favorite dividend growth ideas. On September 19, the company raised its dividend nearly 8%, to $0.42 per share on a quarterly basis.
Sep 22, 2017
Best in Biotech? Global Blood Therapeutics' Promising Treatment for Sickle Cell Anemia
Image Source: National Institute for Health. We remain impressed with the depth of research conducted over a wide host of disease states. Though a molecule may appear to hold significant promise in the pre-clinical phase, we have often witnessed the unique ability of the human body to react to various treatments. Often an unwanted side effect can torpedo a treatment, thus relegating millions of dollars of research obsolete. However, if a promising molecule is brought to market, the payoff is often well worth the effort. Our goal is to sift through the various clinical data to unearth the most promising treatments with the understanding that nothing is assured until the FDA authorizes the product for marketing in the US. We believe we have identified a promising junior biotech in the rare drug field with a promising treatment for sickle-cell anemia.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.